LPMD Algorithm: Methylation Disorder and Azacitidine Response in DNMT3A-Mutant AML

A dataset containing results from the Local Promoter Methylation Disorder (LPMD) algorithm analysis of acute myeloid leukemia (AML) patients. The data includes findings from multiple cohorts, including GSE62298 (68 patients), TCGA-LAML (194 patients), and a validation cohort for azacitidine response (63 patients). It was authored by Xin Liu and last updated on March 18, 2026.

Use Cases

• Predicting azacitidine treatment response in high-risk MDS/secondary AML patients based on a 5-DMDR panel.
• Analyzing bidirectional epigenetic disruption (aberrant stabilization vs. maintenance failure) associated with DNMT3A mutations.
• Monitoring treatment dynamics by tracking changes in LPMD scores over a 3-5 month window.
• Investigating methylation disorder patterns across genomic features like CpG islands, shores, and 5'UTR-Exon1 regions.

Strengths

• Algorithm validated across multiple independent cohorts, including TCGA-LAML (n=194) and a WGBS cohort (20 samples).
• The derived 5-DMDR predictive panel achieved an AUC of 0.777 with 81% sensitivity and 73% specificity.
• Longitudinal analysis includes 153 samples for tracking treatment dynamics.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small in size (477.7 KB), indicating a limited scope of raw or summary data.

Provenance

Source

figshare, author Xin Liu.

Collection Method

Analysis derived from public genomic datasets (GSE62298, TCGA-LAML, GSE152710) using the developed LPMD algorithm.

Freshness

Last updated 2026-03-18 05:21:25